| Background and Objective:Polycystic ovary syndrome (PCOS) is a multifactorial, heterogeneous and the most common endocrine and metabolic disorder in women. The clinical expression varies but commonly includes menstrual disorder, hirsutism, infertility and the presence of polycystic ovaries. It has a tremendous negative impact on the metabolism and physiology of the body as it might develop into a metabolic syndrome with hyperinsulinemia, hypertension, abdominal obesity and dyslipidemia presenting as frequent metabolic features and culminating in serious long-term consequences, such as type2diabetes mellitus, cardiovascular disease and endometrial hyperplasia.Nesfatin-1, a recently discovered anorectic hypothalamic neuropeptide, not only suppresses nocturnal food intake and water drinking but also significantly enhanced glucose-stimulated insulin secretion (GSIS) to exert anti-hyperglycemic effects. Meanwhile, nesfatin-1plays an important role in the process of anti-inflammation and anti-apotosis. It also increases mean arterial pressure (MAP) in conscious. Some researches reported that nesfatin-1is closely linked with puberty onset, epilepsy, stress and depressive disorders, and so on.Nesfatin-1, derives from the precursor NEFA/nucleobindin2(NUCB2), can cross the blood-brain barrier (BBB) without saturation. It is composed of82amino acids and is highly conserved in humans, rats and mice. It was firstly identified in the cytoplasm, but not in the nucleus, of the hypothalamic neurons, and then in the other central areas, such as the pituitary, the spinal cord, the brain stem, etc. It also localized in insular β cells, gastric X/A like cells, adipose cells and gonadular cells. But until now it seems like that nesfatin-1has not been studied in PCOS patients. So the aim of our study is to clarify the relationship between nesfatin-1and PCOS and to explore whether nesfatin-1play a role in the pathophisiology of PCOS.Materials and methods:The study group (n=29) was recruited from the Clinics of Reproductive Hospital affiliated to Shandong University according to the Chinese Diagnosis Criteria For PCOS; the control group was composed of healthy females who have regular mense, thyroid stimulating hormone (TSH) and prolactin(PRL) level, no hyperandrogenism (either clinical or biochemical), no presence of polycystic ovaries and no diabetes,etc. First draw the blood to acquire total RNA, and then do relative quantitative RT-PCR to test the expression of nesfatin-1. SPSS16.0package software was used for statistical analyses.Results:The expression of nesfatin-1in the study group is significantly lower than the control group ((1.06±0.18vs.1.73±0.21, respectively, P﹤05). There are no differences between the two groups in the following aspects:age, height,blood pressure, blood glucose, follicular stimulating hormone (FSH), estradiol (E2), PRL, TSH, alanine aminotransferase (ALT),high density lipoprotein (HDL) and menarche age (P>0.05). But there are significantly differences between PCOS patients and normal females in weight, waist circumference, hip circumference, body mass index (BMI), waist-hip circumference ratio (WHR), luteinizing hormone (LH), LH/FSH, testosterone (T) glutamyl transpeptadase (GGT),total cholesterol (TC), low density lipoprotein (LDL) and total glycerol (TG). However, after correlation tests, we have not detect any significant correlation between nesfatin-1and the aboved parameters.Conclusion:PCOS patients had significantly lower levels of nesfatin-1than healthy controls. Nesfatin-1may play a very important role in the development of PCOS, which need further research. |
PDF Full Text Request